You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科-B(06622.HK)旗下乾眼症藥物臨牀試驗最後一名患者已完成給藥
阿思達克 07-12 16:39
兆科眼科-B(06622.HK)公佈,入組環孢素A眼凝膠(公司主要候選藥物之一)用於治療乾眼症第III期臨牀試驗的最後一名患者已於2021年7月9日完成給藥。

於中國進行此第III期臨牀試驗旨在評估環孢素A眼凝膠對中重度乾眼症患者的療效及安全性,涉及41個臨牀試驗中心,自2020年12月起招募合共644名患者入組,招募工作於2021年4月中提早完成。此試驗的患者退出率約爲7%,反映研究的遵醫囑性理想。此外,數據顯示安全性亦符合預期。公司計劃於2021年底前向國家藥品監督管理局提交新藥申請。

環孢素A眼凝膠是公司於中國開發以供治療乾眼症的創新環孢素凝膠。有別於Restasis,環孢素A眼凝膠是專利水凝膠,其專利權已於中國以至國際範圍獲批。在第II期試驗中,此一創新藥方提升環孢素A於眼表的藥物代謝動力學效能,對乾眼症起到與Restasis類近的療效。然而,與Restasis及其仿製藥每天兩次給藥相比,公司的環孢素A眼凝膠只需每天一次給藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account